Update on hereditary neuropathy

Clinical Neurology

Volumn 44, Issue 11, 2004, Pages 991-994

  Nakagawa, Masanori ^a   Takashima, Hiroshi ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Axonal; Demyelinating; Genotype phenotype correlation; Hereditary neuropathies; Therapy

Indexed keywords

CONFERENCE PAPER; DEMYELINATION; DNA REPAIR; EGR2 GENE; ELECTROPHYSIOLOGY; GDAP1 GENE; GENE; GENE DOSAGE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; GJB1 GENE; HISTOPATHOLOGY; HUMAN; MPZ GENE; MTMR13 GENE; MTMR2 GENE; NDRG1 GENE; NEUROPATHY; PMP22 GENE; POINT MUTATION; PRX GENE; SBF2 GENE; SOX10 GENE;

DEMYELINATING DISEASES; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 10944225139     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Saifi GM, Szigeti K, Snipes GJ, et al: Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Investig Med 2003; 51: 261-283
2. Zuchner S, Mersiyanova IV, Muglia M, et al: Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-451
3. Takashima H, Boerkoel CF, John J, et al: Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002; 32: 267-272
4. Date H, Onodera O, Tanaka T, et al: Early-onset ataxia with ocular motor apraxia and hypoalbuminemia, a variant form of Friedreich's ataxia, is caused by mutations in a novel HIT superfamily protein, aprataxin. Nat Genet 2001; 29: 184-188
5. Moreira MC, Klur S, Watanabe M, et al: Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004; 36: 225-227
6. Ohnishi T, Yamashita A, Kashima I, et al: Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol Cell 2003; 12: 1187-1200
7. Inoue K, Khajavi M, Tomoko Ohyama T, et al: Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004; 36: 361-369
8. Ando Y, Terazaki H, Nakamura M, et al: A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation 2004; 77: 345-349
9. Sereda MW, Meyer zu Hörste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9: 1533-1537
10. Passage E, Norreel JC, Noack-Fraissignes P, et al: Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10: 396-401